AnaptysBio (NASDAQ: ANAB) CLO reports tax-cover sales, grants equity

Rhea-AI Filing Summary

AnaptysBio, Inc.’s chief legal officer Eric J. Loumeau reported equity award activity and related share sales. On January 6, 2026, 5,545 restricted stock units (RSUs) were settled into the same number of common shares for no cash consideration, and he received a new grant of 17,100 RSUs plus a stock option for 23,200 shares with a $43.91 exercise price.

On January 7, 2026, he reported several sales of common stock at weighted average prices around the mid‑$40s per share, including blocks such as 2,017 shares at $45.11 and 5,281 shares at $45.3839. Footnotes state that some shares were sold to cover tax withholding on RSU vesting and that the transactions were executed under a Rule 10b5‑1 trading plan. Following these transactions, he directly held 9,157 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOUMEAU ERIC J

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		M		5,545	A	(1)	18,796	D
Common Stock	01/07/2026		S(2)		2,017	D	$45.11	16,779	D
Common Stock	01/07/2026		S(3)		5,281	D	$45.3839(4)	11,498	D
Common Stock	01/07/2026		S(3)		1,841	D	$46.1301(5)	9,657	D
Common Stock	01/07/2026		S(3)		500	D	$47.23	9,157	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/06/2026		M			5,545	(6)	(6)	Common Stock	5,545	$0	5,545	D
Restricted Stock Unit	(1)	01/06/2026		A		17,100		(7)	(7)	Common Stock	17,100	$0	17,100	D
Stock Option (right to buy)	$43.91	01/06/2026		A		23,200		(8)	01/05/2036	Common Stock	23,200	$0	23,200	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

3. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.87 to $45.835 per share, inclusive. The reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.96 to $46.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

7. The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

8. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did AnaptysBio (ANAB) report in this Form 4?

The Form 4 shows that chief legal officer Eric J. Loumeau had RSUs vest into 5,545 common shares, received a new grant of 17,100 RSUs and a 23,200‑share stock option, and reported multiple common stock sales in the mid‑$40s per share.

Were the AnaptysBio insider stock sales discretionary or pre‑planned?

Footnotes explain that certain shares were sold to cover tax withholding from RSU vesting and that the reported transactions were effected under a Rule 10b5‑1 trading plan adopted by the reporting person on April 11, 2025.

What new equity awards did the AnaptysBio CLO receive?

On January 6, 2026, he received 17,100 RSUs and a stock option for 23,200 shares with a $43.91 exercise price. The RSUs vest 25% annually starting January 6, 2027, and the option vests 25% on January 6, 2027, then monthly in 1/48 increments until fully vested.

At what prices did the AnaptysBio insider sell common stock?

On January 7, 2026, reported weighted average sale prices included $45.11, $45.3839 and $46.1301 per share, with ranges noted in the footnotes (for example, from $44.87 to $45.835 and from $45.96 to $46.83).

How many AnaptysBio shares did the CLO hold after these transactions?

After the reported sales and RSU settlement, the chief legal officer directly held 9,157 shares of AnaptysBio common stock.

How do the reported RSUs in this AnaptysBio filing vest?

One RSU grant vests 25% annually starting on January 6, 2024, and another vests 25% annually starting on January 6, 2027, in each case subject to continued service on each vesting date.